Postmenopausal women may have a new advantage in weight management.
The study indicates a 35% greater weight loss with combined therapies.
Tirzepatide is an obesity drug that shows promising results.
Strategic angle: A Mayo Clinic study reveals that postmenopausal women using hormone therapy alongside tirzepatide experienced significant weight loss.
Postmenopausal women may have a new advantage in weight management.
The study indicates a 35% greater weight loss with combined therapies.
Tirzepatide is an obesity drug that shows promising results.